Third line chemotherapy in patients with metastatic breast cancer: an evaluation of quality of life and cost
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.springerlink.com/index/pdf/10.1023/A:1006123721205
Reference41 articles.
1. Priestman T, Baum M, Jones V, Forbes J: Comparative trial of endocrine versus cytotoxic treatment in advanced breast cancer. Br J Med 1: 1248–1250, 1977
2. Coates A, Gebski V, Bishop JF, Jeal PN, Woods SL, Snyder RD, Tatersall MH, Bryne M, Harvey V, Gill G: Improving the quality of life during chemotherapy for advanced breast cancer: A comparison of intermittent and continuous treatment strategies. N Engl J Med 317: 1490–1495, 1987
3. Tannock IF, Boyd NF, DeBoer G, Erlichman C, Fine S, Larocque G, Mayers C, Perrault D: A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic cancer. J Clin Oncol 6: 1377–1387, 1998
4. Gregory WM, Smith P, Richards MA, Twelves CJ, Knight RK, Rubens RD: Chemotherapy of advanced breast cancer: Outcome and prognostic factors. Br J Cancer 68: 988–995, 1993
5. Cox EB, Burton CV, Olsen GA, Vugrin D: Cisplatin and etoposide: An effective treatment for refractory breast cancer. Am J Clin Oncol 12: 53–56, 1989
Cited by 32 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma;European Journal of Haematology;2021-06-23
2. Health state utility values in locally advanced and metastatic breast cancer by treatment line: a systematic review;Expert Review of Pharmacoeconomics & Outcomes Research;2016-08-30
3. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer;Breast Cancer Research and Treatment;2016-08-29
4. Structural Uncertainty of Markov Models for Advanced Breast Cancer;Medical Decision Making;2016-01-11
5. Prospective construction and validation of a prognostic score to identify patients who benefit from third-line chemotherapy for metastatic breast cancer in terms of overall survival: The METAL3 Study;Contemporary Clinical Trials;2015-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3